JonesResearch raised the firm’s price target on Crinetics (CRNX) to $97 from $85 and keeps a Buy rating on the shares after the company pre-announced Palsonify Q4 revenue and Phase 2 TouCAHn cohort 4 atumelnant data in congenital adrenal hyperplasia. The firm says both results exceeded its expectations. Atumelnant “looks highly competitive” in CAH, preserving “impressive” A4 reductions of 67% during GC taper, the analyst tells investors in a research note. Jones increased Crinetics’ probability of success in CAH to 65% from 45%.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- Crinetics (CRNX): Robust Atumelnant CAH Data, De-Risked Phase 3, and Strong Execution Underpin Buy Rating
- Crinetics price target raised to $90 from $80 at Evercore ISI
- RBC Capital would be a buyer of Neurocrine on weakness following competitor data
- Crinetics reports Q4 PALSONIFY U.S. preliminary net product revenue of over $5M